Viral Vector
Development & Manufacturing
Accelerate your therapies’ journey from laboratory to patient.
The need for highly specific vector expertise is at the core of this scientific shift, as unique as the therapies you develop. There is no universal blueprint; your work deserves a custom-crafted strategy to swiftly and safely bring life-saving therapies to those in need.
The Scientist behind HEK293
While working in the Netherlands in the 1970s, genetic engineer and virologist Dr. Frank Graham developed the Calcium Phosphate Transfection technique and created the HEK293 cell line, now a cornerstone of gene therapy, vaccine development, and viral vector production.
Partnering with Us, You Accelerate Your Path to Market
In viral vector development, the journey from concept to clinical application demands a combination of scientific know-how and commercial experience, core expertise of the professionals working at NecstGen. We facilitate your translational journey within a state-of-the-art, GMP-compliant development and manufacturing facility, ensuring your project meets the highest standards.
Our team is adept at crafting meticulously tailored process designs to meet your therapies’ distinct needs. We are well-versed in the nuances of scaling up production to clinically relevant volumes, an essential step to meet increasing demand while maintaining the integrity of your product.
Our Product Expertise
Lentiviruses (LV)
Ideal for stable gene delivery, with a track record of safety and efficacy.
Adeno-Associated Viruses (AAV)
The vector of choice for targeting various tissues with minimal immune response.
Oncolytic Viruses
Harnessing the power of virotherapy to selectively target and destroy cancer cells.
Continuity through Product Development
Our commitment to scalability spans every trial phase in viral vector manufacturing, ensuring you can access state-of-the-art production capabilities when it matters most. From the crucial early stages of pre-clinical studies or toxicology material production, NecstGen provides robust support in developing and manufacturing viral vectors.
As your therapy progresses, we ensure the seamless transition from one phase to the next, providing reliable and high-quality viral vector supplies from pre-clinical to Phase III clinical trials.
This continuity is the cornerstone of our service, guaranteeing not just consistency in the product but also confidence in the process. It allows our scientific partners to focus on the pivotal task of advancing their therapies through the trial phases toward ultimate regulatory approval and patient application.
Cut Lentivirus Costs for CAR T by 55% with Smarter Transfection.
See how NecstGen slashed plasmid DNA use and dropped lentiviral vector costs by thousands per batch without sacrificing the functional titer. This poster breaks down the Design of Experiments (DoE) approach that made it happen.
Working on Viral Vectors?
These on-demand webinars cover real-world strategies for optimising design, production, and scale-up. Watch any session that fits your focus and get insights you can use now.
Webinar Improving Lentiviral Vector Yield with 2G UNic™ Technology
Improving Lentiviral Vector Yield with 2G UNic™ Technology Lentiviral vectors (LVs) are indispensable for ex vivo gene therapies, but producing them at scale while maintaining high quality and yield remains a major challenge. In this expert-led webinar, you’ll learn...
Webinar Reducing Lentivirus Costs
Discover how our Design of Experiments (DOE) methodology optimises cost-efficiency in GMP manufacturing to turn a refined lab process into a scalable, GMP-ready protocol.
Webinar LV Process for CAR T
Shifting from traditional, ad hoc methodologies to a structured, data-based development approach to create a scalable, GMP-ready process.
Kinga Nowicka, MSc — Head of Viral Vectors
Kinga brings 10+ years in viral‑vector development and manufacturing. At NecstGen she leads process development and clinical production for CGT programs. Prior roles include leading process development at King’s College London’s Innovation Hubs for Gene Therapies (AAV & LV, automation and tech transfer) and senior leadership in vector PD at Autolus and Oxford Biomedica, where she also co‑authored CMC sections for regulatory filings (INDs, amendments, Type B/C, BLAs). MSc Drug Design & Biomedical Sciences (2012, Edinburgh).
